Company intelligence / Profile preview
Celon Pharma S.A.
Lomianki/Warsaw area, Polandcelonpharma.com ↗
- Ownership
- Private
- Employees
- ~515
- Development stage
- Other
01
Overview
Celon Pharma has demonstrated positive Phase II results for several programs including a PDE10A inhibitor for schizophrenia and Parkinson’s disease dyskinesia, an esketamine-based therapy for drug-resistant depression, a second-generation GPR40 agonist in type II diabetes entering Phase II trials, and the world’s first dual JAK/ROCK inhibitor showing promise in autoimmune diseases such as rheumatoid arthritis. The company also markets generic drugs across Europe.[2][6][8][10]
- Therapeutic areas
- OncologyEndocrinologyNeurologyImmunology
- Modalities
- Small molecules (e.g., CPL’36 PDE10A inhibitor, CPL’280 GPR40 agonist)Inhalation drugsDual inhibitors (e.g., JAK/ROCK dual inhibitor)Esketamine-based therapies[6][8][10]
- Industry
- Biotech
02
Drug pipeline
19 assets18 more assets in the full pipeline.
03
Partnerships
Strategic science and business partnerships mentioned but not specifically named publicly.[8]
Beyond the preview
Go deeper on Celon Pharma S.A..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Celon Pharma S.A..